{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:44:58Z","timestamp":1794300298827,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-alcoholic fatty liver disease (NAFLD) has become the most common causes of liver disease in children and adolescents. Although several reports have confirmed the significant correlation between NAFLD and growth hormone (GH)-insulin-like growth factor 1(IGF-1) axis, no study further investigates whether or not recombinant human GH (rhGH) treatment can improve NAFLD in obese children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study was a randomized, open-label study comprising 44 boys with obesity and NAFLD (11.76\u2009\u00b1\u20091.67\u00a0year) to evaluate the effects of 6\u00a0months of rhGH administration for boys with obesity and NAFLD. The subjects were randomized divided into treatment group (subjects with recombinant human GH (rhGH)) and control group for 6\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After 6\u00a0months, IGF-1 increased significantly during rhGH treatment, in comparison with the control group (582.45\u2009\u00b1\u2009133.00 vs. 359.64\u2009\u00b1\u2009129.00\u00a0ng\/ml; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). A significant reduction in serum alanine aminotransferase(ALT) (15.00 vs. 28.00 U\/L; <jats:italic>p<\/jats:italic>\u2009=\u20090.001), aspartate aminotransferase(AST) (20.00 vs. 24.50U\/L; <jats:italic>p<\/jats:italic>\u2009=\u20090.004), gamma glutamyl transferase(GGT) (14.50 vs. 28.50 U\/L; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) was observed in the GH-treated boys. In addition, the rhGH group showed a significant decrease in C reactive protein (CRP) (1.17\u2009\u00b1\u20090.76 vs. 2.26\u2009\u00b1\u20091.43\u00a0mg\/L) and body mass index standard deviation scores (BMI SDS) (2.28\u2009\u00b1\u20090.80 vs. 2.71\u2009\u00b1\u20090.61) than the control group (<jats:italic>p<\/jats:italic>\u2009=\u20090.003, <jats:italic>p<\/jats:italic>\u2009=\u20090.049 respectively). GH treatment also reduced low density lipoprotein cholesterol (LDL-C) (2.19\u2009\u00b1\u20090.42 vs. 2.61\u2009\u00b1\u20090.66\u00a0mmol\/L; <jats:italic>p<\/jats:italic>\u2009=\u20090.016) and increased high density lipoprotein cholesterol (HDL-C) (1.30 vs. 1.15\u00a0mmol\/L; <jats:italic>p<\/jats:italic>\u2009=\u20090.005), and there were no changes in total cholesterol (TC), triglycerides (TG) and uric acid(UA) between the treatment group and the control group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings suggest that 6\u00a0months treatment with rhGH may be beneficial for liver enzyme and can improve obesity-related other cardiovascular and metabolic complications in boys with obesity and NAFLD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-00967-y","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T04:31:56Z","timestamp":1645849916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Jiang","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"key":"967_CR1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.metabol.2016.01.008","volume":"65","author":"M Crespo","year":"2016","unstructured":"Crespo M, Lappe S, Feldstein AE, Alkhouri N. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism. 2016;65:1161\u201371.","journal-title":"Metabolism"},{"key":"967_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"MB Vos","year":"2017","unstructured":"Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram SS, Xanthakos SA. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children. J Pediatr Gastroenterol Nutr. 2017;64:319\u201334.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"967_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"967_CR4","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/petr.12819","volume":"20","author":"T Gilliland","year":"2016","unstructured":"Gilliland T, Dufour S, Shulman GI, Petersen KF, Emre SH. Resolution of non-alcoholic steatohepatitis after growth hormone replacement in a pediatric liver transplant patient with panhypopituitarism. Pediatr Transplant. 2016;20:1157\u201363.","journal-title":"Pediatr Transplant"},{"key":"967_CR5","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1053\/j.gastro.2006.12.024","volume":"132","author":"Y Takahashi","year":"2007","unstructured":"Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R, Imanaka M, Nishizawa H, Takahashi M, Seo Y. Growth Hormone Reverses Nonalcoholic Steatohepatitis in a Patient With Adult Growth Hormone Deficiency. Gastroenterology. 2007;132:938\u201343.","journal-title":"Gastroenterology"},{"key":"967_CR6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/hep.20140","volume":"39","author":"LA Adams","year":"2004","unstructured":"Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology. 2004;39:909\u201314.","journal-title":"Hepatology"},{"key":"967_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ghir.2014.07.002","volume":"24","author":"R Matsumoto","year":"2014","unstructured":"Matsumoto R, Fukuoka H, Iguchi G, Nishizawa H, Bando H, Suda K, Takahashi M, Takahashi Y. Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency. Growth Horm IGF Res. 2014;24:174\u20139.","journal-title":"Growth Horm IGF Res"},{"key":"967_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/EJE-12-0252","volume":"167","author":"H Nishizawa","year":"2012","unstructured":"Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, Yamamoto M, Suda K, Takahashi M, Seo Y. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol. 2012;167:67\u201374.","journal-title":"Eur J Endocrinol"},{"key":"967_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ghir.2012.10.001","volume":"23","author":"A Sirbu","year":"2013","unstructured":"Sirbu A, Gologan S, Arbanas T, Copaescu C, Martin S, Albu A, Barbu C, Pirvulescu I, Fica S. Adiponectin, body mass index and hepatic steatosis are independently associated with IGF-I status in obese non-diabetic women. Growth Horm IGF Res. 2013;23:2\u20137.","journal-title":"Growth Horm IGF Res"},{"key":"967_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jpeds.2014.01.052","volume":"165","author":"S Cianfarani","year":"2014","unstructured":"Cianfarani S, Inzaghi E, Alisi A, Germani D, Puglianiello A, Nobili V. Insulin-Like Growth Factor-I and -II Levels Are Associated with the Progression of Nonalcoholic Fatty Liver Disease in Obese Children. J Pediatr. 2014;165:92\u20138.","journal-title":"J Pediatr"},{"key":"967_CR11","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1210\/en.2014-1010","volume":"155","author":"J-E Guidotti","year":"2014","unstructured":"Guidotti J-E, Gilgenkrantz H, Baud V, Billot K, Vons C, Ziol M, Helmy N, Fauveau V, Prip-Buus C, Zerrad-Saadi A. Collin de l\u2019Hortet A: GH Administration Rescues Fatty Liver Regeneration Impairment by Restoring GH\/EGFR Pathway Deficiency. Endocrinology. 2014;155:2545\u201354.","journal-title":"Endocrinology"},{"key":"967_CR12","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3390\/ijms19051339","volume":"19","author":"C Daniel","year":"2018","unstructured":"Daniel C, Claudio CV, Nancy S, Diego SM, Catalina C, Margarita P, Juan A, Johanna A, Fabi\u00e1n C, Betzab\u00e9 I. Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation. Int J Mol Sci. 2018;19:1339.","journal-title":"Int J Mol Sci"},{"key":"967_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1476-511X-9-78","volume":"9","author":"Y Qin","year":"2010","unstructured":"Qin Y. Tian Y-p: Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. Lipids Health Dis. 2010;9:78.","journal-title":"Lipids health dis"},{"key":"967_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/cen.14344","volume":"94","author":"CS Pan","year":"2021","unstructured":"Pan CS, Weiss JJ, Fourman LT, Buckless C, Branch KL, Lee H, Torriani M, Misra M, Stanley TL. Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease. Endocrinol (Oxf). 2021;94:183\u201392.","journal-title":"Endocrinol (Oxf)"},{"key":"967_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/apa.13685","volume":"106","author":"S Liang","year":"2017","unstructured":"Liang S, Cheng X, Hu Y, Song R, Li G. Insulin-like growth factor 1 and metabolic parameters are associated with nonalcoholic fatty liver disease in obese children and adolescents. Acta Paediatr. 2017;106:298\u2013303.","journal-title":"Acta Paediatr"},{"key":"967_CR16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1055\/s-0043-124970","volume":"50","author":"S Liang","year":"2018","unstructured":"Liang S, Yu Z, Song X, Wang Y, Li M, Xue J. Reduced Growth Hormone Secretion is Associated with Nonalcoholic Fatty Liver Disease in Obese Children. Horm Metab Res. 2018;50:250\u20136.","journal-title":"Horm Metab Res"},{"key":"967_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12944-018-0721-9","volume":"17","author":"S Liang","year":"2018","unstructured":"Liang S, Xue J, Li G. Effects of recombinant human growth hormone administration on cardiovascular risk factors in obese children with relative growth hormone deficiency. Lipids Health Dis. 2018;17:66.","journal-title":"Lipids health dis"},{"key":"967_CR18","first-page":"1","volume":"2020","author":"J Wu","year":"2020","unstructured":"Wu J, Zhao F, Zhang Y, Xue J, Kuang J, Jin Z, Zhang T, Jiang C, Wang D, Liang S. Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity. Biomed Res Int. 2020;2020:1\u20138.","journal-title":"Biomed Res Int"},{"key":"967_CR19","first-page":"493","volume":"47","author":"H Li","year":"2009","unstructured":"Li H, Ji CY, Zong XN, Zhang YQ. Body mass index growth curves for Chinese children and adolescents aged 0 to 18 years. Chin J Pediatr. 2009;47:493\u20138.","journal-title":"Chin J Pediatrics"},{"key":"967_CR20","first-page":"18","volume":"49","author":"The Chinese National Workshop on Fatty Liver and AlcoholLiverDiseasefor the Chinese Liver Disease Association","year":"2010","unstructured":"The Chinese National Workshop on Fatty Liver and AlcoholLiverDiseasefor the Chinese Liver Disease Association. Guidelines for management of nonalcoholic fatty liver disease. Chin J Hepatol. 2010;49:18\u201320.","journal-title":"Chin J Hepatol"},{"key":"967_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/jc.2016-2573","volume":"102","author":"DM Styne","year":"2017","unstructured":"Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, Yanovski JA. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102:709\u201357.","journal-title":"J Clin Endocrinol Metab"},{"key":"967_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/adc.51.3.170","volume":"51","author":"JM Tanner","year":"1976","unstructured":"Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 1976;51:170\u20139.","journal-title":"Arch Dis Child"},{"key":"967_CR23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"D Matthews","year":"1985","unstructured":"Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412\u20139.","journal-title":"Diabetologia"},{"key":"967_CR24","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"Matsuda M, Defronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462.","journal-title":"Diabetes Care"},{"key":"967_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbrc.2012.05.115","volume":"423","author":"H Nishizawa","year":"2012","unstructured":"Nishizawa H, Takahashi M, Fukuoka H, Iguchi G, Kitazawa R, Takahashi Y. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. Biochem Biophys Res Commun. 2012;423:295\u2013300.","journal-title":"Biochem Biophys Res Commun"},{"key":"967_CR26","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.ghir.2020.101332","volume":"53-54","author":"E Villanueva-Ortega","year":"2020","unstructured":"Villanueva-Ortega E, M\u00e9ndez-Garc\u00eda LA, Garibay-Nieto GN, Laresgoiti-Servitje E, Medina-Bravo P, Olivos-Garc\u00eda A, Mu\u00f1oz-Ortega MH, Ventura-Ju\u00e1rez J, Escobedo G. Growth hormone ameliorates high glucose-induced steatosis on in vitro cultured human HepG2 hepatocytes by inhibiting de novo lipogenesis via ChREBP and FAS suppression. Growth Horm IGF Res. 2020;53\u201354:101332.","journal-title":"Growth Horm IGF Res."},{"key":"967_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1478-3231.2008.01823.x","volume":"29","author":"A Riquelme","year":"2009","unstructured":"Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, P\u00e9rez-Ayuso RM, Gonz\u00e1lez R, Alvarez M, Hern\u00e1ndez V, Garc\u00eda-Zattera MJ, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int. 2009;29:82\u20138.","journal-title":"Liver Int"},{"key":"967_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00535-007-2060-x","volume":"42","author":"M Yoneda","year":"2007","unstructured":"Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007;42:573\u201382.","journal-title":"J Gastroenterol"},{"key":"967_CR29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4103\/jfmpc.jfmpc_887_19","volume":"9","author":"R Kumar","year":"2020","unstructured":"Kumar R, Porwal YC, Dev N, Kumar P, Chakravarthy S, Kumawat A. Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian Indians: A cross-sectional study. J Family Med Prim Care. 2020;9:390\u20134.","journal-title":"J Family Med Prim Care"},{"key":"967_CR30","first-page":"848","volume":"277","author":"CH Gravholt","year":"1999","unstructured":"Gravholt CH, Schmitz O, Simonsen L, B\u00fclow J, Christiansen JS, M\u00f8ller N. Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue. Am J Physiol. 1999;277:848\u201354.","journal-title":"Am J Physiol"},{"key":"967_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1210\/jc.2008-1357","volume":"94","author":"KC Mekala","year":"2008","unstructured":"Mekala KC, Tritos NA. Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. J Clin Endocrinol Metab. 2008;94:130\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"967_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1530\/EJE-11-1068","volume":"166","author":"MA Bredella","year":"2012","unstructured":"Bredella MA, Lin E, Brick DJ, Gerweck AV, Harrington LM, Torriani M, Thomas BJ, Schoenfeld DA, Breggia A, Rosen CJ. Effects of growth hormone in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial. Eur J Endocrinol. 2012;166:601.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"967_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2265.2010.03815.x","volume":"74","author":"LA Behan","year":"2011","unstructured":"Behan LA, Monson JP, Agha A. The interaction between growth hormone and the thyroid axis in hypopituitary patients. Clin Endocrinol (Oxf). 2011;74(3):281\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"967_CR34","doi-asserted-by":"publisher","first-page":"101331","DOI":"10.1016\/j.ghir.2020.101331","volume":"53\u201354","author":"L Hou","year":"2020","unstructured":"Hou L, Liang Y, Wu W, Lin HH, Luo XP, Ying YQ. Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children. Growth Horm IGF Res. 2020;53\u201354:101331.","journal-title":"Growth Horm IGF Res"},{"key":"967_CR35","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/MPG.0b013e318252a13f","volume":"54","author":"P Vajro","year":"2012","unstructured":"Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U, Durmaz O, Lacaille F, McLin V, Nobili V. Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012;54:700\u201313.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"23","key":"967_CR36","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","volume":"293","author":"JP Chanoine","year":"2005","unstructured":"Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873\u201383.","journal-title":"JAMA"},{"issue":"9","key":"967_CR37","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1210\/jc.2013-2063","volume":"98","author":"MA Bredella","year":"2013","unstructured":"Bredella MA, Gerweck AV, Lin E, Landa MG, Torriani M, Schoenfeld DA, Hemphill LC, Miller KK. Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity. J Clin Endocrinol Metab. 2013;98(9):3864\u201372.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-00967-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-00967-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-00967-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T04:32:06Z","timestamp":1645849926000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-00967-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-00967-y","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,26]]},"assertion":[{"value":"7 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of The Second Hospital, Cheeloo College of Medicine, Shandong University. All the patients and their parents written informed consent. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}